NEW YORK (GenomeWeb News) — A pan-European project created to discover biomarkers for monitoring and following patients with breast and colon cancer has received a €2.9 million ($3.9 million) grant from the European Union, project partner Ipsogen said today.
The nine-member project, called Colon and Breast Cancer Diagnostics, or COBRED, is being coordinated by Paris-based Biosystems International, and the funding is being administered under the EU’s Sixth Framework Program.
Ipsogen said that COBRED after three years aims to deliver a set of biomarker candidates that have been verified in preclinical studies and will be ready for large-scale clinical validation, development, and commercialization by the three corporate biotech partners.
In addition to Biosystems International and Ipsogen, the Austrian metabolomics company Biocrates is involved in the project.
The consortium has three academic partners, including Austria’s University of Innsbruck, Estonia’s University of Tartu, and Hungary’s University of Debrecen.
COBRED also will use resources such as bio-samples from two French cancer centers, including Paris’ Curie Institute and the Gustave Roussy Institute in Villejuif.
Ipsogen said that although COBRED is focused on biomarkers for follow-up diagnostics, the research could potentially develop an early cancer-detection and screening tool.
Ipsogen CEO Vincent Fert called the project “a powerful research platform” for “aggregating major technologies and clinical expertise” that will develop tools for monitoring breast and colon cancers.